Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Albitar

Showing results (191-200 of 214) with videos related to

Pageof 22
Sort By:
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
Leukemia Research|May 26, 2004
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemiaAnne-Marie O'Farrell, Helene A Yuen, Beverly Smolich, et al.
Biotechnology Research International|March 24, 2016
Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic MalignanciesMahmoud Aljurf, Hala Abalkhail, Amal Alseraihy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Leukemia Research|April 1, 2006
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemiaFrancis Giles, Srdan Verstovsek, Stefan Faderl, et al.
Frontiers in Oncology|July 1, 2022
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid NeoplasmsAndrew Ip, Alexandra Della Pia, Gee Youn Geeny Kim, et al.
Cancer|March 15, 2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian, Jean-Pierre J Issa, Craig S Rosenfeld, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Blood Advances|December 13, 2018
GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cellsMoonjung Jung, Stefan Cordes, Jizhong Zou, et al.
Pageof 22

Showing results (191-200 of 214) with videos related to

Sort By:
Pageof 22
Cancer|March 26, 2003
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemiaApostolia M Tsimberidou, Hagop M Kantarjian, Jorge Cortes, et al.
Leukemia Research|May 26, 2004
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemiaAnne-Marie O'Farrell, Helene A Yuen, Beverly Smolich, et al.
Biotechnology Research International|March 24, 2016
Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic MalignanciesMahmoud Aljurf, Hala Abalkhail, Amal Alseraihy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.
Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.
Leukemia Research|April 1, 2006
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemiaFrancis Giles, Srdan Verstovsek, Stefan Faderl, et al.
Frontiers in Oncology|July 1, 2022
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid NeoplasmsAndrew Ip, Alexandra Della Pia, Gee Youn Geeny Kim, et al.
Cancer|March 15, 2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian, Jean-Pierre J Issa, Craig S Rosenfeld, et al.
The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.
Blood Advances|December 13, 2018
GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cellsMoonjung Jung, Stefan Cordes, Jizhong Zou, et al.
Pageof 22